CEO SUMMARY: In response to the steep ramp-up in the utilization of genetic and molecular testing, the nation’s largest health insurers are preparing to institute new guidelines for coverage and reimbursement. These will include pre-authorization by physicians, a more effective genetic test coding arrangement for claims submission by laboratories, and implementation of evidence-based medicine (EBM) […]
Pre-authorization Coming For Pricey Molecular Tests
Health insurers ready to control utilization of expensive genetic and molecular tests
- By Robert Michel
- > From the Volume XVII No. 6 - April 19, 2010 Issue
- Tags: cap, care contracts, clia, clia and cap, clinical lab, clinical laboratories, Clinical Laboratory, clinical laboratory industry, clinical labs, coding and billing, cpt, cpt code, diagnostic testing, genetic test, hedis, lab administrator, lab industry, lab test, laboratories, laboratory industry, laboratory management services, laboratory test, laboratory test utilization, managed care, managed care companies, managed care contract, managed care contracts, managed care plan, managed care plans, medical management, molecular diagnostic, molecular diagnostic test, molecular diagnostic testing, molecular lab, molecular testing, molecular tests, ncqa, pathologists, personalized medicine, test utilization, the clinical laboratory, the laboratory
